Pharmaceutical

J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Oct 24, 2024 - 04:00
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.
Read the original article

Tags:

Previous Article

Be Bio raises $82m to advance haemophilia B gene therapy to Phase I/II trial

Next Article

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

CRISPR is about to make history. Here’s the 5-minute ru...

Dec 9, 2023

STAT+: Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis

STAT+: Novo Nordisk is concluding research on Wegovy’s ...

Nov 5, 2023

The potential of 3D printing in drug development and delivery

The potential of 3D printing in drug development and de...

Jul 26, 2024